Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease

Recruiting now

Conditions studied: Stroke, Action Speed, Dementia Mild Cognitive Impairment, Alzheimer Disease

In brief

A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. In stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. In neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage remains unknown and this diagnostic requires new tests. Finally, in terms of anatomical determinants, few studies have studied the determinants of action slowing. The objectives of this project are to Determine the diagnostic and prognostic value of action slowing assessed with new quick tests in patients with acute stroke (Neurovascular Unit) and cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), Fronto Temporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)) and to define the lesion determinants with VBM and VLSM

Key facts

Study ID: NCT05785156
Run by: Centre Hospitalier Universitaire, Amiens
People needed: 129
Starts: 2021-07-16
Expected to finish: 2027-07-16
Last updated by the study team: 2026-05-13

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients between 40 and 85 years old,
French native language,
Social Security affiliation.
University Memory Clinic for: Mild severity disorder (MMSE> 19) or major severity disorder related to AD : Albert 2011 criteria ; McKhann 2011
to MCL according to McKeith criteria
to FTLD according to Rascovsky 2011 criteria
BBD according to Armstrong's criteria
related to PSP according to Höglinger criteria

You may not qualify if…

Mental retardation or guardianship
Previously diagnosed dementia
Other current or past brain condition
severe head trauma
epilepsy prior to stroke still requiring previous treatment
Parkinson disease, multiple sclerosis...
brain tumor or brain radiation therapy
Current or past schizophrenia or psychosis
Active or past psychiatric disorders requiring a stay> 2 days in a specialized environment
Contra indication to MRI
Comorbidity with life expectancy <1 year
Comorbidity affecting cognition in particular:
Alcohol (> 3 glasses / day) or history of alcohol withdrawal syndrome
opiate or cocaine addiction or opiate withdrawal syndrome
renal failure (dialysis or creatinine clearance <30)
hepatic failure (spontaneous INR> 1.5 or PT <60%)
respiratory failure requiring oxygen therapy
heart failure (orthopnea> 2 pillows)
persistent vigilance disturbances (NIHSS1a score ≤1)
cancer with paraneoplastic syndrome
treatment with gold salts, D Penicillamine or other treatment with cognitive effect
Patient under guardianship or curators or private under public law
Pregnant and / or lactating wom

Where it is running

CHU Amiens — Amiens, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.